The results of Phase III trials of the CD20-targeted human monoclonal antibody (mAb) ofatumumab in rheumatoid arthritis and non-Hodgkin's lymphoma (NHL) dampen hopes on the potential of the drug ...

The first-in-class drug – which targets CD20 and CD3 – is being assessed by the regulator for relapsed or refractory FL, the most common slow-growing form of non-Hodgkin lymphoma (NHL), after ...

ICP-B02 is a bispecific antibody designed to bind CD20 on tumour cells and CD3 on T ... in China for relapsed/refractory ...

Plamotamab (formerly XmAb 13676) is currently in phase 1 testing in patients with CD20-expressing cancers, including chronic lymphocytic leukaemia (CLL), non-Hodgkin's lymphoma (NHL) and B-cell ...